Comparison of efficacy and toxicity of FC and FCR regimens in primary B-cell chronic lymphocytic leukemia: a retrospective study
| Autor: | Ye. А. Stadnik, Ye. А. Nikitin, B. V. Biderman, G. N. Salogub, Yu. Yu. Lorie, N. N. Tsyba, Yu. A. Alexeeva, V. A. Doronin, V. N. Mashuk, R. I. Vabishevich, A. L. Melikyan, T. I. Kolosheinova, L. Yu. Kolosova, A. B. Sudarikov, L. G. Kovaleva, A. Yu. Zaritsky |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Онкогематология, Vol 0, Iss 1-2, Pp 39-46 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1818-8346 2413-4023 |
| DOI: | 10.17650/1818-8346-2008-0-1-2-39-46 |
| Popis: | Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell lymphocytic leukemia were the main goals of this retrospective study. It has been demonstrated that inclusion of Rituximab into the FC regimen improves outcome of patients with B-cell lymphocytic leukemia without significant increase of toxicity. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|